Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA in vivo CAR-T for Relapsed and Refractory Autoimmune Diseases
NCT07388212Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1 trial of CD19/BCMA in vivo CAR-T in autoimmune disease (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 2 years and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
CD19/BCMA in vivo CAR-T
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07388212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388212.